Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The role of induction chemotherapy (IC) for eyeball preservation has not been established in head and neck squamous cell carcinoma (HNSCC) of the paranasal sinus and nasal cavity (PNSNC). Periorbital involvement frequently leads to eyeball exenteration with a margin of safety. We evaluated the treatment outcomes, including survival and eyeball preservation, of patients who received IC for HNSCC of the PNSNC. Methods: We reviewed 21 patients diagnosed with HNSCC of the PNSNC who were treated with IC. We analyzed response, eyeball preservation rate, and overall survival. Results: Tumors were located in the paranasal sinus (n = 14) or nasal cavity (n = 7). Most patients had stage T4a (n = 10) or T4b (n = 7) disease. More than half of the patients received a chemotherapy regimen of docetaxel, fluorouracil, and cisplatin (n = 11). Thirteen patients (61.9%) achieved a partial response after IC and 15 patients (71.4%) achieved T down-staging. Among 17 patients with stage T4 disease, which confers a high risk of orbital exenteration, 14 (82.4%) achieved preservation of the involved eye. The 3-year overall survival (OS) rate of patients who achieved a partial response to IC was 84.6%. The 3-year OS rate of patients with stable disease or disease progression after IC was 25.0% (p = 0.038). Conclusions: IC could be considered for down-staging patients with advanced T-stage disease. It could also be a reasonable option for eyeball preservation in locally advanced HNSCC of the PNSNC.
Abstract
Background/Aims: The role of induction chemotherapy (IC) for eyeball preservation has not been established in head and neck squamous cell carcinoma (HNSCC) of the paranasal sinus and nasal cavity (PNSNC). Periorbital involvement frequently leads to eyeball exenteration with a margin of safety. We evaluated the treatment outcomes, including survival and eyeball preservation, of patients who received IC for HNSCC of the PNSNC. Methods: We reviewed 21 patients diagnosed with HNSCC of the PNSNC who were treated with IC. We analyzed response, eyeball preservation rate, and overall survival. Results: Tumors were located in the paranasal sinus (n = 14) or nasal cavity (n = 7). Most patients had stage T4a (n = 10) or T4b (n = 7) disease. More than half of the patients received a chemotherapy regimen of docetaxel, fluorouracil, and cisplatin (n = 11). Thirteen patients (61.9%) achieved a partial response after IC and 15 patients (71.4%) achieved T down-staging. Among 17 patients with stage T4 disease, which confers a high risk of orbital exenteration, 14 (82.4%) achieved preservation of the involved eye. The 3-year overall survival (OS) rate of patients who achieved a partial response to IC was 84.6%. The 3-year OS rate of patients with stable disease or disease progression after IC was 25.0% (p = 0.038). Conclusions: IC could be considered for down-staging patients with advanced T-stage disease. It could also be a reasonable option for eyeball preservation in locally advanced HNSCC of the PNSNC.
참고문헌 (32)
- Siegel R, "Cancer statistics, 2012", CA Cancer J Clin, 62, pp.10~29 (2012)
- Batsakis JG, "Tumours of the Head and Neck: Clinical and Pathological Considerations" (1979), Lippincott Williams and Wilkins
- Pignon JP, "Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93randomised trials and 17,346 patients", Radiother Oncol, 92, pp.4~14 (2009)
- Haddad RI, "Recent advances in head and neck cancer", N Engl J Med, 359, pp.1143~1154 (2008)
- Forastiere AA, "Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer", N Engl J Med, 349, pp.2091~2098 (2003)
- Tobias JS, "Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial", Lancet Oncol, 11, pp.66~74 (2010)
- Dulguerov P, "Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review", Cancer, 92, pp.3012~3029 (2001)
- Ganly I, "Craniofacial resection for malignant paranasal sinus tumors: report of an international collaborative study", Head Neck, 27, pp.575~584 (2005)
- Guntinas-Lichius O, "Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients", Eur J Surg Oncol, 33, pp.222~228 (2007)
- Snyers A, "Malignant tumors of the nasal cavity and paranasal sinuses: longterm outcome and morbidity with emphasis on hypothalamic-pituitary deficiency", Int J Radiat Oncol Biol Phys, 73, pp.1343~1351 (2009)
- Ahmad K, "Squamous cell carcinoma of the maxillary sinus", Arch Otolaryngol, 107, pp.48~51 (1981)
- Marchetta FC, "Squamous cell carcinoma of the maxillary antrum", Am J Surg, 118, pp.805~807 (1969)
- McCary WS, "Preservation of the eye in the treatment of sinonasal malignant neoplasms with orbital involvement: a confirmation of the original treatise", Arch Otolaryngol Head Neck Surg, 122, pp.657~659 (1996)
- Perry C, "Preservation of the eye in paranasal sinus cancer surgery", Arch Otolaryngol Head Neck Surg, 114, pp.632~634 (1988)
- The Department of Veterans Affairs Laryngeal Cancer Study Group, "Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer", N Engl J Med, 324, pp.1685~1690 (1991)
- Lefebvre JL, "Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial: EORTC Head and Neck Cancer Cooperative Group", J Natl Cancer Inst, 88, pp.890~899 (1996)
- Lee YY, "Superselective intra-arterial chemotherapy of advanced paranasal sinus tumors", Arch Otolaryngol Head Neck Surg, 115, pp.503~511 (1989)
- Rosen A, "Locoregionally advanced paranasal sinus carcinoma:favorable survival with multimodality therapy", Arch Otolaryngol Head Neck Surg, 119, pp.743~746 (1993)
- Papadimitrakopoulou VA, "Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma", Cancer, 98, pp.2214~2223 (2003)
- Hitt R, "Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer", J Clin Oncol, 23, pp.8636~8645 (2005)
- Vermorken JB, "Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer", N Engl J Med, 357, pp.1695~1704 (2007)
- Posner MR, "Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer", N Engl J Med, 357, pp.1705~1715 (2007)
- Jang NY, "Definitive radiotherapy with or without chemotherapy for T3-4N0 squamous cell carcinoma of the maxillary sinus and nasal cavity", Jpn J Clin Oncol, 40, pp.542~548 (2010)
- Hanna EY, "Induction chemotherapy for advanced squamous cell carcinoma of the paranasal sinuses", Arch Otolaryngol Head Neck Surg, 137, pp.78~81 (2011)
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Edge SB, "AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual" (2010), Springer
- Cohen EE, "DeCIDE:a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC)in patients with N2", N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN), 2012, pp.30(15 Suppl), 5500~
- Haddad R, "Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial", Lancet Oncol, 14, pp.257~264 (2013)
- Hitt R, "A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer", Ann Oncol, 25, pp.216~225 (2014)
- Ghi MG, "Concomitant chemoradiation (CRT) or cetuximab", RT (CET, cisplatin, pp.5-fluorouracil (TPF)followed by CRT or CET, RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN): a randomized phase III factorial study (NCT01086826)[DOI]
- Rajapurkar M, "Oncologic and functional outcome of the preserved eye in malignant sinonasal tumors", Head Neck, 35, pp.1379~1384 (2013)
- Nishino H, "Multidisciplinary therapy consisting of minimally invasive resection, irradiation, and intra-arterial infusion of 5-fluorouracil for maxillary sinus carcinomas", Head Neck, 35, pp.772~778 (2013)